Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.53 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.40 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 3,396 | 0.73 |
| pathways Reactome | 27 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 11467
Earlier readings: 2026-10-26 0.47; 2026-10-25 0.47; 2026-10-24 0.47; 2026-10-23 0.47.
Sealed predictions
- CDKN1A in dopamine neurons, braak-0.50 (p 0.168) → -0.57 (p 0.111)receipt 0170
Swarm cases
receipt 0170: CDKN1A in dopamine neurons, braak
- power
- full sample -0.43 (p 0.072, n 18), 95% CI -0.75 to +0.04. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.47 (p 0.050, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.050, n 18). not the mix.
- skeptic
- leave-one-out range -0.51 to -0.36, sign flips 0; without severely affected donors -0.43 (p 0.072, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CDKN1A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts